Sermorelin legal status: the dated approval and access record

The status, in plain words

Here is the sermorelin legal status read carefully and in order. Sermorelin was once an FDA-approved prescription medicine — the formerly-approved branded product, with an NDA on file — used to diagnose and treat growth-hormone deficiency in children ^[1][8]. That product was taken off the US market in 2008, and the reason matters: it was a commercial (business) decision, not a finding that the drug was unsafe or ineffective ^[5][9].

Because it is no longer sold as a finished branded drug, sermorelin today is made one prescription at a time by compounding pharmacies. The FDA treats it as a long-standing "Category 1" bulk drug substance under its interim Section 503A policy, with final guidance issued in January 2025 — meaning the agency does not intend to take enforcement action against this category of compounding ^[9]. Separately, it is banned in competitive sport ^[11]. Each of those facts is dated and sourced below; none of this page is a place to buy anything.

Is sermorelin FDA approved? The approval history, dated

Not currently as a finished drug — but the history is specific. Sermorelin acetate was FDA-approved (the former branded product, NDA on file) for idiopathic growth-hormone deficiency and short stature in children ^[1]. It was withdrawn from the US market in 2008 for commercial reasons, not safety or efficacy problems ^[5][9].

That withdrawal had a real clinical consequence: a 2009 clinical review noted the resulting absence of commercially available recombinant GHRH in the United States and discussed implications for diagnosing adult GH deficiency, including a shift toward alternative stimulation tests ^[8]. So "is sermorelin FDA approved?" is best answered with the dated record: yes historically, as a branded product; no today as a finished drug; and presently available through compounding under a defined FDA category.

Compounding standing: Category 1 under Section 503A

Sermorelin is treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A policy, the framework that governs pharmacy compounding of customized medications for individual patients; the agency's final guidance was issued in January 2025 ^[9]. This standing is time-sensitive and nuanced, and one distinction is worth stating clearly: sermorelin's situation is not the same as that of certain other GH-axis peptides (such as ipamorelin and kisspeptin-10) that were reviewed by the Pharmacy Compounding Advisory Committee in October 2024. Those reviews should not be conflated with sermorelin's Category 1 footing. A 2026 review of therapeutic peptides likewise frames most newer, unapproved peptides as promising but not yet ready for routine human use without further study ^[10].

WADA status: prohibited in sport (S2)

Growth hormone secretagogues, including GHRH and its analogs such as sermorelin, are on the WADA Prohibited List under the S2 hormone-and-metabolic-modulator class — prohibited at all times, in and out of competition ^[11]. Dedicated LC-MS/MS detection methods for GHRH analogs have been developed, and athletes who use these compounds face anti-doping consequences. A 2026 critical review of peptide and peptide-analog use in recreational and professional sport concludes these substances remain experimental, with poorly defined long-term risks and an unregulated supply chain, and should be considered high-risk in competitive and recreational settings ^[10].